Acurx Pharmaceuticals Secures New Patent for Innovative Antibiotic Technology
Acurx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to creating a new breed of small molecule antibiotics for complex bacterial infections, announced a significant stride in its innovation strategy on February 2, 2026, with the granting of a new patent by the United States Patent and Trademark Office (USPTO). The patent number, US 12,534,470, encompasses key elements related to DNA Polymerase IIIC inhibitors, including compositions, methods of use, and pharmaceutical formulations. This development not only bolsters Acurx's intellectual property portfolio but also marks the latest addition to its growing list of patents both in the United States and internationally.
To date, Acurx has successfully secured four patents within the United States and has additional patents granted in countries like Israel, Japan, India, and Australia. These protections are critical for the company’s ACX-375C program, which is specifically aimed at targeting DNA Polymerase IIIC, an essential enzyme in bacterial DNA replication.
Robert J. DeLuccia, the Executive Chairman of Acurx, expressed enthusiasm regarding this new patent, highlighting its importance for the broader development efforts of the company’s antibiotic solutions facilitated by an AI-supported drug discovery platform. Acurx believes that its innovative treatment approaches could significantly transform how serious and potentially fatal infections are managed. Presently, data on microbiome selectivity related to new compounds has emerged as promising, suggesting that these novel antibiotics may offer a class effect, distinguishing themselves from traditional antibiotics like linezolid.
Acurx is advancing particularly with its leading DNA Polymerase IIIC inhibitor, ibezapolstat, which is nearing Phase 3 readiness for treating C. difficile infections. This inhibitor stands apart by validating the bacterial target for DNA Polymerase IIIC, thereby fostering supportive evidence for its clinical efficacy. Early-phase studies on novel compounds developed in Acurx’s preclinical pipeline reveal that these candidates may be effectively absorbed in clinical settings for various applications, such as treating acute bacterial skin infections (ABSSSI, including methicillin-resistant Staphylococcus aureus), community-acquired bacterial pneumonia, and even infectious endocarditis or inhalational anthrax triggered by Bacillus anthracis, which is classified as a bioterrorism threat.
The advancements made by Acurx Pharmaceuticals are crucial not just for the company but for the broader medical community grappling with resistant bacterial strains and challenging infections. As Acurx prepares to escalate its clinical trial activities internationally, the ongoing research and developments reflect a dedicated commitment to innovation aimed at substantial public health improvements. The company’s antibiotic candidates are particularly designed to target Gram-positive bacteria like Clostridioides difficile, MRSA, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae, thereby enriching the available therapeutic options.
For more information about Acurx Pharmaceuticals and their pioneering initiatives in antibiotic development, you can visit their website at www.acurxpharma.com. As Acurx plans to advance its clinical programs, the outlook remains optimistic, with their promising new patent providing a solid foundation as they move forward in combatting persistent and dangerous bacterial infections.
It's important to note that forward-looking statements are made based on current expectations and involve risks and uncertainties, including whether ibezapolstat will receive the needed approvals for market entry and whether production and distribution strategies will be successful. Investors and stakeholders are encouraged to keep these considerations in mind as Acurx continues its project developments.
To date, Acurx has successfully secured four patents within the United States and has additional patents granted in countries like Israel, Japan, India, and Australia. These protections are critical for the company’s ACX-375C program, which is specifically aimed at targeting DNA Polymerase IIIC, an essential enzyme in bacterial DNA replication.
Robert J. DeLuccia, the Executive Chairman of Acurx, expressed enthusiasm regarding this new patent, highlighting its importance for the broader development efforts of the company’s antibiotic solutions facilitated by an AI-supported drug discovery platform. Acurx believes that its innovative treatment approaches could significantly transform how serious and potentially fatal infections are managed. Presently, data on microbiome selectivity related to new compounds has emerged as promising, suggesting that these novel antibiotics may offer a class effect, distinguishing themselves from traditional antibiotics like linezolid.
Acurx is advancing particularly with its leading DNA Polymerase IIIC inhibitor, ibezapolstat, which is nearing Phase 3 readiness for treating C. difficile infections. This inhibitor stands apart by validating the bacterial target for DNA Polymerase IIIC, thereby fostering supportive evidence for its clinical efficacy. Early-phase studies on novel compounds developed in Acurx’s preclinical pipeline reveal that these candidates may be effectively absorbed in clinical settings for various applications, such as treating acute bacterial skin infections (ABSSSI, including methicillin-resistant Staphylococcus aureus), community-acquired bacterial pneumonia, and even infectious endocarditis or inhalational anthrax triggered by Bacillus anthracis, which is classified as a bioterrorism threat.
The advancements made by Acurx Pharmaceuticals are crucial not just for the company but for the broader medical community grappling with resistant bacterial strains and challenging infections. As Acurx prepares to escalate its clinical trial activities internationally, the ongoing research and developments reflect a dedicated commitment to innovation aimed at substantial public health improvements. The company’s antibiotic candidates are particularly designed to target Gram-positive bacteria like Clostridioides difficile, MRSA, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae, thereby enriching the available therapeutic options.
For more information about Acurx Pharmaceuticals and their pioneering initiatives in antibiotic development, you can visit their website at www.acurxpharma.com. As Acurx plans to advance its clinical programs, the outlook remains optimistic, with their promising new patent providing a solid foundation as they move forward in combatting persistent and dangerous bacterial infections.
Forward-Looking Statements
It's important to note that forward-looking statements are made based on current expectations and involve risks and uncertainties, including whether ibezapolstat will receive the needed approvals for market entry and whether production and distribution strategies will be successful. Investors and stakeholders are encouraged to keep these considerations in mind as Acurx continues its project developments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.